Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Dasatinib for Androgen-Deprived Progressive Prostate Cancer
2006-002205-31Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in prostate cancer (PCa), sponsored by Bristol Myers Squibb. Primary endpoint: Primary efficacy response rate. Started Oct 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-002205-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002205-31.